

It is illegal to post this copyrighted PDF on any website.

CME Background

Articles are selected for credit designation based on an assessment of the educational needs of CME participants, with the purpose of providing readers with a curriculum of CME articles on a variety of topics throughout each volume. Activities are planned using a process that links identified needs with desired results.

To obtain credit, read the article, correctly answer the questions in the Posttest, and complete the Evaluation.

CME Objective

After studying this article, you should be able to:

- Screen for obsessive-compulsive symptoms in patients with major depressive disorder

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.



Credit Designation

The CME Institute of Physicians Postgraduate Press, Inc., designates this journal-based CME activity for a maximum of 1 *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1 hour of Category I credit for completing this program.

Date of Original Release/Review

This educational activity is eligible for *AMA PRA Category 1 Credit*[™] through December 31, 2017. The latest review of this material was November 2015.

Financial Disclosure

All individuals in a position to influence the content of this activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. In the past year, Alan J. Gelenberg, MD, Editor in Chief, has been a consultant for Zynx Health and Bloom Burton, has received grant/research support from Pfizer, and has been a stock shareholder of Healthcare Technology Systems. No member of the CME Institute staff reported any relevant personal financial relationships. **Faculty financial disclosure appears at the end of the article.**

Prevalence and Impact of Obsessive-Compulsive Symptoms in Depression: A STAR*D Report

Lee Baer, PhD^{a,*}; Madhukar H. Trivedi, MD^b; Ilana Huz, BA^a; A. John Rush, MD^c; Stephen R. Wisniewski, PhD^d; and Maurizio Fava, MD^a

ABSTRACT

Objective: Obsessive-compulsive symptoms (OCS) may be underrecognized in patients suffering from major depressive disorder. These patients may not receive optimal psychopharmacologic or psychological treatment if their OCS are not attended to. We performed a secondary analysis of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial database, the largest effectiveness study of “real-world” depression ever conducted, to determine the frequency of OCS and their effects on depression outcome.

Method: 3,984 adult subjects without a previous selective serotonin reuptake inhibitor trial for their current major depressive episode, per *DSM-IV* diagnostic criteria, had data for rating scales of interest at entry into Level 1 of the STAR*D trial, a 12-week open trial of citalopram at a dose of 20–60 mg/d to assess rates of depression remission. Our primary interest was the OCD subscale of the Psychiatric Diagnostic Screening Questionnaire.

Results: At study entry, 53% of the STAR*D sample (which excluded patients with primary obsessive-compulsive disorder) endorsed ≥ 1 OCS, and 14% endorsed ≥ 4 OCS. Subjects endorsing ≥ 4 OCS had significantly lower corrected odds of depression remission on both the 17-item Hamilton Depression Rating Scale (HDRS-17) (OR=0.61) and the Quick Inventory of Depressive Symptomatology (odds ratio [OR]=0.51). Number of OCS endorsed was positively correlated with HDRS-17 score ($r=0.26$, $P<.0001$). Consistent with findings from the Dunedin, New Zealand Community Study, the most common obsessions were doubts of having inadvertently caused harm and violent obsessions.

Conclusions: OCS are common in depressed outpatients and are often not attended to. They impact clinical recovery from depression and should be screened for since sufferers are often reluctant to disclose these symptoms.

Trial Registration: ClinicalTrials.gov identifier: NCT00021528

J Clin Psychiatry 2015;76(12):1668–1674

[dx.doi.org/10.4088/JCP.14m09670](https://doi.org/10.4088/JCP.14m09670)

© Copyright 2015 Physicians Postgraduate Press, Inc.

^aDepartment of Psychiatry, Massachusetts General Hospital, Boston

^bDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas

^cDuke-National University of Singapore, Singapore

^dHealth Policy Institute, University of Pittsburgh, Pittsburgh, Pennsylvania

*Corresponding author: Lee Baer, PhD, Massachusetts General Hospital, 1 Bowdoin Sq, 6th floor, Boston, MA 02114 (lbaer@partners.org).

Obsessive-compulsive disorder (OCD) imposes a severe burden of illness on its sufferers around the world.^{1–3} Yet, obsessive-compulsive symptoms (OCS) remain widely underrecognized or misdiagnosed by mental health professionals around the world: only 28% of patients meeting *DSM-IV* criteria for OCD at 14 German psychiatric clinics had been diagnosed with this problem,⁴ and when mental health professionals were presented with vignettes of patients with OCS, 77% misdiagnosed homosexual obsessions and 43% misdiagnosed aggressive obsessions.⁵ One reason for the

It is illegal to post this copyrighted PDF on any website.

It is illegal to post this copyrighted PDF on any website.

underrecognition of OCS is that sufferers are particularly reluctant to discuss repugnant, embarrassing, and stigmatized violent or sexual obsessions with treaters: among Spanish OCD sufferers, the main barrier to help-seeking was “fears of stigma and the meaning of the thought contents,”⁶ perhaps an understandable concern since a recent survey found that, when presented with a case vignette of an OCD sufferer with filicidal obsessions, only 62% of psychiatrists and trainees included OCD in their differential diagnosis, and, among these, 48% included involuntary psychiatric admission in their management recommendations.⁷

The symptoms of OCD are heterogeneous, but tend to involve obsessive themes of contamination, symmetry, superstition, inadvertently causing harm, or repugnant sexual, violent, or religious obsessions.^{8,9} These thoughts are distinguishable from the negative automatic thoughts involving themes of loss and failure¹⁰ that are common in depression. More than half of the general population also experiences unwanted intrusive thoughts, images, and impulses about sex, violence, or harm,¹⁰ but less persistently than and with less distress than with true OCS.

The cognitive-behavioral theory of OCS argues that depressed mood increases the frequency and intensity of intrusive thoughts¹¹ and that inaccurate appraisals of these obsessions as being dangerous or very important lead to rituals (eg, cleaning, checking, reassurance-seeking, counting, repeating) to reduce distress. These rituals are negatively reinforced by temporary relief from the obsession, but prevent exposure to the obsessions and the opportunity to correct their misappraisals.⁹

There is evidence for a strong overlap between OCS and major depressive disorder (MDD),¹² particularly a current episode of MDD.¹³ For example, Fullana et al¹⁴ analyzed data from the prospective Dunedin, New Zealand community study and found that 49% of individuals with major depression without comorbid OCD endorsed 1 or more OCS by age 32, most commonly repugnant thoughts and obsessions about inadvertently causing harm. OCS involving “thoughts of hurting the baby” are so common in postpartum depression as to be considered a symptom of the disorder.^{15,16} Finally, the *ICD-10* clinical description for OCD¹⁷ indicates that OCS are highly prevalent in depression.

These findings—underrecognition of OCS and overlap of depression and OCS—lead to two clinically relevant questions: How common are unattended OCS in individuals seeking treatment for depression? Do unattended OCS adversely affect depression remission with medication treatment? These questions are important because they may result in millions of individuals around the world missing the chance for benefits from depression treatment.

We reasoned that a secondary analysis of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D)¹⁸ trial database would provide data relevant to these research questions. We focused only on the first level of the trial, 12-week open treatment of depressed adults (who had not been treated with a selective serotonin reuptake inhibitor [SSRI] medication for the current major depressive episode)

- Obsessive-compulsive symptoms are frequently present in depressed outpatients, yet are often not attended to because sufferers are often reluctant to disclose these often embarrassing symptoms.
- Depressed patients should be asked directly about comorbid obsessive-compulsive symptoms because, if present, these symptoms can negatively impact clinical recovery from depression.

with citalopram at a dose of 20–60 mg/d, and not on later steps, which were intended to define the next best treatment if citalopram did not produce remission.¹⁸

The STAR*D trial (ClinicalTrials.gov Identifier: NCT00021528) was the largest effectiveness study of “real-world” depression ever conducted, enrolling more than 4,000 patients enrolled at 21 academic, clinic, and primary care sites across the United States, and focusing on remission of depressive symptoms as the primary endpoint. Although the STAR*D trial did not include a priori hypotheses about the impact of OCS, the study design specifically included the self-report Psychiatric Diagnostic Screening Questionnaire (PDSQ)¹⁹ at screening to assess for “concurrent psychiatric diagnoses.”²⁰ A secondary post hoc analysis on the STAR*D dataset documented the negative impact on depression remission of such anxiety and substance abuse symptoms as measured by the PDSQ.²¹ However, no study to date has examined OCS because the STAR*D trial excluded primary OCD and because “the neurobiology and course of illness of obsessive-compulsive disorder distinguishes itself from other anxiety disorders.”^{21(p250)} Hence, any OCS self-reported by participants would have been unattended to because they were (1) unrecognized, (2) judged to be secondary to depression, or (3) judged to be subclinical.

Our primary aims in this secondary analysis of this large cohort of depressed subjects in Level 1 of the STAR*D trial were (1) to estimate the occurrence of OCS in this large sample of depressed outpatients and (2) to determine the impact of unattended OCS on depression remission with citalopram.

METHOD

Study Design and Patients

This study analyzed data collected as part of the STAR*D trial, which was designed to determine optimal treatment steps for outpatients with nonpsychotic MDD whose depression did not remit as a result of initial treatment with the SSRI citalopram. Complete rationale, design, and methods of the STAR*D trial have been described elsewhere.¹⁸ Briefly, this effectiveness trial attempted to maximize generalizability to “real-world” patients by enrolling more than 4,000 depressed outpatients aged 18–75 years seeking care in US outpatient general medical or psychiatric treatment settings between 2001 and 2004 who met criteria for *DSM-IV* MDD with an entry score of 14 or higher on the 17-item Hamilton Depression Rating Scale (HDRS-17).²² Exclusion criteria

It is illegal to post this copyrighted PDF on any website.

included bipolar disorder, anorexia nervosa or bulimia, psychotic symptoms or disorders, and, most relevant for the present study, a current primary diagnosis of OCD based on clinical interview (but not based upon the PDSQ or any structured diagnostic interview).

This report focused on baseline rating scales collected at entry for 3,984 subjects who had data for the variables of interest at entry into Level 1 of the STAR*D trial, in which all subjects underwent up to a 12-week open trial of citalopram at a dose between 20 and 60 mg/d.¹⁸ We did not focus on later steps in STAR*D, which focused on medication nonremitters in Level 1.

All procedures were approved by the institutional review board, and all risks, benefits, and adverse events associated with each treatment within the randomized treatments were explained to study participants, who were required to provide written informed consent prior to study participation.

Procedures

We obtained the STAR*D Level 1 data files from the coordinating site and converted them into STATA and SPSS formats for our statistical analyses. To capture subjects' self-report of any OCS at study entry, our primary interest was in the obsessive-compulsive subscale of the PDSQ^{19,20} completed at study entry of the STAR*D trial to screen for concurrent psychiatric disorder symptoms. The Ns in this report may differ from those in other STAR*D outcome studies because they include all subjects who completed the relevant rating scales at entry into the study.

The full PDSQ consists of 139 yes/no self-report questions divided into subscales for each of the major *DSM-IV* Axis I psychiatric diagnoses. Our primary interest was in the 8 items constituting the obsessive-compulsive subscale of the PDSQ. These items ask the patient to answer whether he or she has experienced problems during the past 2 weeks in the following areas: (1) worrying obsessively about dirt, germs, or chemicals; (2) worrying obsessively that something bad would happen because of forgetting to do something important (eg, locking a door, turning off a stove, pulling out electrical plugs); (3) worrying obsessively about acting or speaking violently when you really didn't want to; (4) feeling compelled to do certain things over and over (for at least half an hour per day) that you could not stop doing when you tried; (5) feeling compelled to do things over and over even though it interfered with getting other things done; (6) obsessively and excessively washing and cleaning yourself or things around you; (7) obsessively and excessively checking or repeating things over and over again; (8) counting things obsessively and excessively.

Like the other PDSQ subscales, the OCD scale has been demonstrated to have good test retest-reliability ($r > 0.80$) and criterion validity compared to the Structured Clinical Interview for *DSM* Disorders (SCID) diagnostic interview.¹⁹ The OCD subscale has a cut-point of 1 obsessive-compulsive symptom endorsed for a sensitivity of 0.90 compared to SCID OCD diagnosis and a cut-point of 4 or more OCS endorsed for specificity of 0.90 compared to SCID OCD diagnoses.¹⁹

We chose these 2 cut-points to indicate mild and more severe degrees of OCS. Because OCD was an exclusion criterion, we did not consider these cut-points to represent an OCD diagnosis, but rather varying levels of OCS severity.

To compare the association between OCS and various severities of depression at entry into the study, we used the entry HDRS-17²³ cut-points of 17 for the comparison of mild versus moderate depression and 24 for the comparison of moderate versus severe depression found optimal to maximize sensitivity and specificity.²¹

Following the methods of the STAR*D trial primary analyses of Level 1, we determined depression remission rates in 2 ways: (1) final HDRS-17 score of 7 or less with subjects dropped out before the final visit of Level 1 coded as "non-remitted"¹⁸ and (2) Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR)²⁴ final score of 5 or less, using the method of last observation carried forward.¹⁸ We examined depression remission only at the end of Level 1 because thereafter patients were assigned to various second treatments of medication or cognitive-behavioral therapy, decreasing the sample sizes and increasing the complexity of the analyses.

Statistical Analyses

Statistical analyses were conducted with the Statistical Package for the Social Sciences (SPSS) Version 20 (IBM Corporation, Armonk, New York) and included descriptive means and standard deviations for continuous variables and frequencies for categorical variables. Psychometric analyses included principal components analysis, Cronbach coefficient α , and Wilcoxon signed rank test. Inferential statistics included t tests for comparison of means and contingency analysis by χ^2 for comparison of frequencies. Tests of odds ratios for depression remission were conducted using binary logistic regression. Linear regression and correlation was used with continuous and dichotomous variables. Because of the very large sample size, 2-tailed P values of .01 were considered significant, and effect sizes are presented.


RESULTS

Reliability and Validity of PDSQ OCD Subscale

Internal consistency of the 8 items of the PDSQ OCD subscale was adequate as assessed by Cronbach coefficient $\alpha = .78$. The factor structure found by Zimmerman and Mattia¹⁹ for the 13 PDSQ subscales was reproduced by using principal components analysis and retaining 13 factors with varimax rotation, yielding simple structure for the 8 OCD subscale items, each of which had loadings of > 0.40 on the OCD factor and no loadings > 0.20 on any other factor. We were unable to assess test-retest reliability because the PDSQ was administered only at the screen visit. To assess discriminant validity of the PDSQ subscale, we compared the mean and median scores on this 8-item subscale to the median score on the 5-item psychotic experiences (PE) subscale, since, as with primary OCD, psychotic symptoms

It is illegal to post this copyrighted PDF on any website.

Figure 1. Prevalence of 1 or More OCS or 4 or More OCS Endorsed by Entire Sample and by Severity of Depression



Abbreviation: OCS = obsessive-compulsive symptoms.

or disorders were excluded from the STAR*D trial.¹⁸ The means for the OCD and PE subscales were 1.41 and 0.52, respectively (dependent $t_{3,992} = 34.17$, $P < .0001$). The medians for the OCD and PE subscales were 1.0 and 0.0, respectively ($P < .0001$ by Wilcoxon signed rank test).

Frequency of OCS

Our first research question concerned the frequency of OCS in this sample of depressed patients without obvious OCD. Figure 1 demonstrates that more than half of the entire sample endorsed at least 1 OC symptom, and 14% of patients endorsed at least 4 OCS. Figure 1 also illustrates that the proportion of patients endorsing both 1 or more and 4 or more OCS at baseline increased with increasing levels of baseline depression (χ^2 for each obsessive-compulsive symptom by depression level: $P < .001$). The linear-by-linear association between the baseline HDRS-17 depression score and number of OCS endorsed was significant ($\chi^2_1 = 244.88$, $P < .0001$; $r = 0.26$, $P < .0001$), suggesting a dose-response relationship between baseline depression and OCS frequency in this sample.

Table 1 presents a demographic and clinical comparison of depressed outpatients endorsing none versus 1 or more OCS on the PDSQ OCD subscale on entry into the STAR*D trial.

Compared to patients without OCS, patients endorsing 1 or more obsessive-compulsive symptom were significantly more likely (1) to be unemployed, (2) to be younger, (3) to have more severe MDD (as indicated by significantly earlier age at onset of first major depressive episode [MDE], more lifetime MDEs, and higher HDRS-17 and QIDS-SR scores), (4) to have more psychiatric comorbidity as indicated by the number of Axis I diagnoses based on the PDSQ, (5) to have more symptoms of anxious depression as measured by the HDRS-17, and (6) to have more physical illnesses as assessed

Table 1. Demographic and Clinical Comparison of Depressed Patients by Number of OCS (N = 3,984)^a

Variable	Endorsed No OCS	Endorsed ≥ 1 OCS	P
Female, n (%)	1,197 (64)	1,296 (62)	.13
Unemployed, n (%)	623 (33)	840 (40)	<.0001
Age, y	41.8 (13.3)	40.1 (13.2)	<.0001
Age at onset of first MDE, y	26.3 (14.8)	24.6 (13.8)	<.0001
No. of MDEs	5.0 (8.7)	5.8 (9.8)	.01
CIRS severity score	1.2 (0.6)	1.3 (0.6)	<.0001
No. of Axis I diagnoses	0.3 (0.6)	0.4 (0.6)	<.0001
HDRS-17 anxious depression score	5.6 (2.5)	6.7 (2.5)	<.0001
Baseline HDRS-17 score	18.4 (6.4)	21.3 (6.3)	<.0001
Baseline QIDS-SR score	14.6 (4.2)	16.2 (4.2)	<.0001

^aValues shown as mean (SD) unless otherwise noted.

Abbreviations: CIRS = Cumulative Index Rating Scale, HDRS = 17-item Hamilton Depression Rating Scale, MDE = major depressive episode, OCS = obsessive-compulsive symptoms, QIDS-SR = Quick Inventory of Depression Symptomatology–Self-Report Version.

by the Cumulative Index Rating Scale (CIRS) severity score.²⁵ To correct for these differences, these variables and gender were included as covariates in all adjusted logistic and linear regression models.

Since OCS are often heterogeneous both between and within patients, Table 2 illustrates the relative frequencies of the various OCS probed as part of the PDSQ OCD subscale and each obsessive-compulsive symptom's unique association with the 2 depression rating scales used in STAR*D, based on simultaneous linear regression models. As Table 2 indicates, only the 2 OCS related to harming obsessions contributed significant unique predictive value over and above the other OCS at $P < .001$.

When all 8 OCS were simultaneously entered into separate simultaneous ordinal regression equations (using the logit link function) to predict the HDRS-17 and QIDS-SR suicide item scores, only violent obsessions contributed significant, unique variance to the prediction (both $P < .001$).

Impact of OCS on Depression Remission

Our second research question was, if a significant percentage of STAR*D patients had OCS, would this make a practical difference in the effects of their antidepressant medication treatment for depression? Table 3 illustrates that while the sample as a whole remitted at a 28% rate by HDRS-17 criteria at 12 weeks, the remission rate for patients with no OCS was 31%, and remission rates were significantly lower for patients endorsing 1 or more (25%) or 4 or more OCS (18%); a similar pattern was seen on remission as defined by self-reported QIDS score. In all cases, raw remission rates for subjects endorsing 1 or more OCS or ≥ 4 OCS were significantly lower than subjects endorsing no OCS (all $P < .0001$). Table 3 also contains adjusted odds ratios from logistic regression models of remission and unstandardized B weights from linear regression models treating final depression level as a dimensional or continuous variable. These indicate that with correction, all remission and dimensional differences survived correction at $P < .01$ with the exception of subjects endorsing 1 or more OCS and remission on HDRS-17.

Table 2. OCS Items Endorsed in the STAR*D Sample

PDSQ Subscale Item (comparable symptom category in OCD reference sample)	Frequency in STAR*D Sample (n = 3,995)	Unique Association With Baseline HDRS-17 ^a	Unique Association With Baseline QIDS-SR ^a
Obsessions			
"Did you worry obsessively that something bad would happen because you forgot to do something important—like locking the door, turning off the stove, pulling out the electrical cords of appliances, etc?" (pathological doubt)	30.4%	1.23***	0.68***
"Did you worry obsessively that you would act or speak violently when you really didn't want to?" (aggressive)	29.7%	2.49***	1.22***
"Did you worry obsessively about dirt, germs, or chemicals?" (contamination)	11.2%	0.60	0.13
Compulsions			
"Did you obsessively and excessively check or repeat things over and over again?" (checking)	19.0%	0.76*	0.53*
"Were there things you felt compelled to do over and over even though it interfered with getting other things done?" (repeating)	17.0%	0.50	0.22
"Were there things you felt compelled to do over and over (for at least one half hour per day) that you could not stop doing when you tried?" (repeating)	11.9%	0.34	0.48
"Did you wash and clean yourself or things around you obsessively and excessively?" (cleaning)	11.6%	0.20	-0.23
"Did you count things obsessively and excessively?" (counting)	10.0%	0.36	0.32

^aUnstandardized B coefficient from simultaneous linear regression equation. Positive B coefficient indicates the mean increase in baseline depression score if that particular OCS was endorsed, over and above the effects of the other OCS.

*P < .05.

***P < .001.

Abbreviations: HDRS-17 = 17-item Hamilton Depression Rating Scale, OCD = obsessive-compulsive disorder, OCS = obsessive-compulsive symptoms, PDSQ = Psychiatric Diagnostic Screening Questionnaire, QIDS-SR = Quick Inventory of Depression Symptomatology–Self-Report Version, STAR*D = Sequenced Treatment Alternatives to Relieve Depression.

Table 3. Depression Outcomes After 12 Weeks of Treatment With Citalopram by Number of OCS at Study Entry

Measure	Total Sample	Unadjusted			Adjusted OR ^a	
		No OCS	≥ 1 OCS	≥ 4 OCS	≥ 1 OCS	≥ 4 OCS
Remission, %						
HDRS-17	28.0	31.4	25.2 ^b	18.2 ^b	0.85	0.61**
QIDS-SR	30.6	37.2	25.3 ^b	18.7 ^b	0.76**	0.51***
Adjusted B^c						
≥ 1 OCS ≥ 4 OCS						
Endpoint Score, mean (SD)						
HDRS-17	14.0 (9.0)	12.4 (8.5)	15.4 (9.2) ^b	17.8 (9.3) ^b	1.17***	2.02***
QIDS-SR	9.5 (5.9)	8.5 (5.6)	10.3 (6.1) ^b	11.8 (6.2) ^b	0.80***	1.50***

^aOdds of remission compared to No OCS reference group, adjusted for gender, number of MDEs, age, baseline score on HDRS-17, employment status, CIRS severity score, number of Axis I diagnoses, age at first MDE, and number of anxious depression symptoms on HDRS-17.

^bSignificantly different from No OCS group by t test or by χ^2 test, P < .001.

^cUnstandardized B coefficient from multiple linear regression, adjusted for gender, number of MDEs, age, employment status, CIRS severity score, number of Axis I diagnoses, age at first MDE, number of anxious depression symptoms on HDRS-17, and baseline score on respective depression scale.

**P < .01.

***P < .001.

Abbreviations: CIRS = Cumulative Index Rating Scale, HDRS-17 = 17-item Hamilton Depression Rating Scale, MDE = major depressive episode, OCS = obsessive-compulsive symptoms, QIDS-SR = Quick Inventory of Depression Symptomatology–Self-Report Version.

DISCUSSION

Our results indicate that OCS are highly prevalent in depressed outpatients and are commonly not attended to. In a representative sample of nonpsychotic depressed outpatients that excluded primary cases of OCD, the majority endorsed at least 1 obsessive-compulsive symptom—most commonly obsessions about harm, which mirrored the results of the Dunedin community study.¹⁴ Harming obsessions were found to be uniquely related to depression severity in the present study, which is consistent with previous research indicating that they severely impact sufferers' quality of life.²⁶

OCS impacted depression remission and depression improvement as measured by both clinician- and patient-rated measures. A greater number of OCS was associated with lower odds of depression remission. We also observed a close relation between OCS and severity of depression, with frequency of endorsement of all symptoms increasing along with patients' depression level. In addition, presence of OCS was related to more severe depression as indicated by earlier onset of first MDE and more total lifetime MDEs. This finding is consistent with previous research indicating greater impairment in patients with comorbid MDD and OCD.²⁷

Our findings are correlational in nature and cannot indicate direction of causation between depression and OCS, and it is likely that there is a feedback loop between these symptoms. Both depression and obsessions are believed to be linked to dysregulation in the brain's serotonin system,^{9,12} and a recent large twin study found that OCS and depressive symptoms may occur together primarily as a result of shared genetic factors.²⁸

Limitations of our secondary analysis of the existing STAR*D dataset include the absence of a psychometric instrument specifically designed to assess OCS, such as the Yale-Brown Obsessive Compulsive Scale and Symptom Checklist²⁹ (although the PDSQ has demonstrated good criterion validity with a SCID diagnosis of OCD, it has not yet been compared statistically to these other validated measures of obsessive-compulsive severity). In addition, OCS were assessed only at study entry, which prohibited assessment of their change with treatment. Finally, exclusion of patients with primary OCD from the STAR*D trial makes it impossible for us to comment on the prevalence of underrecognized OCD diagnoses in this study. Future studies should address these limitations.

It is illegal to post this copyrighted PDF on any website.

It is illegal to post this copyrighted PDF on any website.

CONCLUSION

OCS are common in depressed outpatients and are often not attended to. They impact clinical recovery from depression and should be screened for, since sufferers are often reluctant to disclose these symptoms. We would expect that OCS are likely to be more common in depressed outpatients, since the STAR*D sample excluded subjects with primary OCD.

Not attending to OCS may result in patients' missing the chance for successful treatment of both their depressive and their obsessive-compulsive symptoms (since treatment of OCD and major depression differ in that [1] specific cognitive-behavioral techniques are generally required for

OCS⁹ and [2] patients with OCS may require a higher dose of antidepressants than patients with major depression).³⁰ These findings highlight the need to improve our training of psychiatric and primary care clinicians to recognize and effectively treat depressed patients with OCS.

The relatively high frequency of OCS present in this sample suggests that screening for OCS in depressed outpatients with questions similar to those in Table 2 would be efficient and would help reduce our patients' suffering. Particularly important OCS symptoms to screen for are harming obsessions, which were the most common in our sample and yet also the symptoms least commonly shared with treaters due to stigma.⁶

Submitted: November 19, 2014; accepted March 12, 2015.

Drug name: citalopram (Celexa and others).

Disclosure of off-label usage: The authors have determined that, to the best of their knowledge, no investigational information about pharmaceutical agents that is outside US Food and Drug Administration-approved labeling has been presented in this activity.

Author contributions: All authors had access to all the data in the study and had final responsibility for the decision to submit for publication.

Financial disclosures: Dr Trivedi is or has been an advisor/consultant to Abbott, Abdi Ibrahim, Akzo (Organon), Alkermes, AstraZeneca, Axon Advisors, Bristol-Myers Squibb Company, Cephalon, Cerecor, Concert, Eli Lilly, Evotec, Fabre-Kramer, Forest, GlaxoSmithKline, Janssen, Johnson & Johnson, Libby, Lundbeck, Meade Johnson, MedAvante, Medtronic, Merck, Mitsubishi Tanabe, Naurex, Neuronetics, Otsuka, PamLab, Parke-Davis, Pfizer, Pgx Health, Phoenix Marketing Solutions, Rexahn, Ridge Diagnostics, Roche, Sepracor, Shire, Sierra, SK Life and Science, Sunovion, Takeda, Tal Medical/Puretech, Targacept, Transcept, VantagePoint, Vivus, and Wyeth-Ayerst and has received research support from Agency for Healthcare Research and Quality, Corcept, Cyberonics, National Alliance for Research on Schizophrenia and Depression (NARSAD), National Institute of Mental Health (NIMH), and National Institute on Drug Abuse (NIDA). Dr Rush reports personal fees from the American Psychiatric Association, NIDA, Eli Lilly, Lundbeck, Medavante, Guilford Press, Penn State Hershey Medical Center, American Society of Clinical Psychopharmacology (ASCP), University of California at San Diego, UT Southwestern Medical Center Dallas, Santium, Stanford University, and Duke-NUS; grants from Duke-NUS; and non-financial support from the International College of Neuropsychopharmacology. Dr Fava has received research support from Abbott; Alkermes; American Cyanamid; Aspect Medical Systems; AstraZeneca; Avani; BioResearch; BrainCells; BristolMyers Squibb; CeNeRx BioPharma; Cephalon; Clintara; Covance; Covidien; Eli Lilly; EnVivo; Euthymics Bioscience; Forest; Ganeden Biotech; GlaxoSmithKline; Harvard Clinical Research Institute; Hoffman-LaRoche; Icon Clinical Research; i3 Innovus/Ingenix; Janssen; Jed Foundation; Johnson & Johnson; Lichtwer; Lorex; Lundbeck; MedAvante; Methylation Sciences; NARSAD; National Center for Complementary and Alternative Medicine; NIDA; NIMH; Neuralstem; Novartis; Organon; PamLab; Pfizer; Pharmacia & Upjohn; Pharmaceutical Research Associates; Pharmavite; Pharma-Rx; Photothera; Reckitt Benckiser; Roche; RCT Logic; SanofiAventis; Shire; Solvay; Stanley Medical Research Institute; Synthelabo; and Wyeth-Ayerst; has been an advisor/consultant for Abbott; Affectis; Alkermes; Amarin; Aspect Medical Systems; AstraZeneca; Auspex; Avani; AxsomeBayer; Best Practice Project Management; BioMarin; Biovail; BrainCells; BristolMyers Squibb; CeNeRx BioPharma; Cephalon; Cerecor; CNS Response; Compellis; Cypress; DiagnoSearch Life Sciences; Dainippon Sumitomo; Dov; Edgemont; Eisai; Eli Lilly; EnVivo; ePharmaSolutions; Epix; Euthymics Bioscience; Fabre-Kramer; Forest; Genomind; GlaxoSmithKline; Grunenthal; i3 Innovus/Ingenix; Janssen; Jazz; Johnson & Johnson; Knoll; Labopharm; Lorex; Lundbeck; MedAvante; Merck; MSI Methylation Sciences; Naurex; Neuralstem; Neuronetics; NextWave; Novartis; Nutrition 21; Orexigen; Organon; Otsuka; PamLab; Pfizer; PharmaStar; Pharmavite; Pharma-Rx; Precision Human Biotechnology; Prexa; Puretech; PsychoGenics; Psylin Neurosciences; RCT Logic; Rexahn; Ridge Diagnostics; Roche; SanofiAventis; Sepracor; Servier; Schering-Plough; Solvay; Somaxon; Somerset; Sunovion; Supernus; Synthelabo; Takeda; Tal Medical; Tetragenex; TransForm; Transcept; and Vanda; has received speaking/publishing fees from Adamed; Advanced Meeting Partners; American Psychiatric Association; ASCP; AstraZeneca; Belvoir Media Group; Boehringer Ingelheim; Bristol-Myers Squibb; Cephalon; Physicians Postgraduate Press; Eli Lilly; Forest; GlaxoSmithKline; Immedex; Massachusetts General Hospital (MGH) Psychiatry Academy/Primedia; MGH Psychiatry Academy/Reed Elsevier; Novartis; Organon; Pfizer; PharmaStar; United BioSource; and Wyeth-Ayerst; has equity holdings in Compellis and PsyBrain; holds a patent for Sequential Parallel Comparison Design, licensed by MGH to Pharmaceutical Product Development, and a patent application for A Combination of Ketamine Plus Scopolamine in Major Depressive Disorder; holds copyrights for the MGH Cognitive & Physical Functioning Questionnaire, the Sexual Functioning Inventory, the Antidepressant Treatment Response Questionnaire, the Discontinuation-Emergent Signs & Symptoms checklist, and the SAFER interview; and receives royalties from Lippincott, Williams & Wilkins; Wolters Kluwer; and World Scientific Publishing. Drs Baer and Wisniewski and Ms Huz have no personal affiliations or financial relationships with any commercial interest to disclose relative to the article.

Funding/support: Chirag Foundation.

Role of the sponsor: The funder of this study had no role in the study design, data collection, data analysis, data interpretation, or writing of this report.

Acknowledgments: Data used in the preparation of this article were obtained from the limited access data sets distributed from the NIH-supported STAR*D. Sequenced Treatment Alternatives to Relieve Depression focused on nonpsychotic major depressive disorder in adults seen in outpatient settings. The primary purpose of this research study was to determine which treatments worked best if the first treatment with medication does not produce an acceptable response. The study was supported by the National Institute of Mental Health (NIMH) Contract # N01MH90003 to the University of Texas Southwestern Medical Center.

Additional information: Requests for access to the STAR*D data set are made to the NIMH, sponsor of the trial. See <http://www.nimh.nih.gov/trials/data-sets/nimh-procedures-for-requesting-data-sets.shtml> for information.

REFERENCES

1. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry*. 2005;62(6):617-627.
2. Subramaniam M, Abdin E, Vaingankar JA, et al. Obsessive-compulsive disorder: prevalence, correlates, help-seeking and quality of life in a multiracial Asian population. *Soc Psychiatry Psychiatr Epidemiol*. 2012;47(12):2035-2043.
3. Gururaj GP, Math SB, Reddy JYC, et al. Family burden, quality of life and disability in obsessive compulsive disorder: an Indian perspective. *J Postgrad Med*. 2008;54(2):91-97.
4. Wahl K, Kordon A, Kuelz KA, et al. Obsessive-Compulsive Disorder (OCD) is still an unrecognized disorder: a study on the recognition of OCD in psychiatric outpatients. *Eur Psychiatry*. 2010;25(7):374-377.
5. Glazier K, Calixte RM, Rothschild R, et al. High rates of OCD symptom misidentification by mental health professionals. *Ann Clin Psychiatry*. 2013;25(3):201-209.
6. Belloch A, Del Valle G, Morillo C, et al. To seek advice or not to seek advice about the problem: the help-seeking dilemma for obsessive-compulsive disorder. *Soc Psychiatry Psychiatr Epidemiol*. 2009;44(4):257-264.
7. Booth BD, Friedman SH, Curry S, et al. Obsessions of child murder: underrecognized manifestations of obsessive-compulsive disorder. *J Am Acad Psychiatry Law*. 2014;42(1):66-74.
8. Pinto A, Mancebo MC, Eisen JL, et al. The Brown Longitudinal Obsessive Compulsive Study: clinical features and symptoms of the sample at intake. *J Clin Psychiatry*. 2006;67(5):703-711.
9. Abramowitz JS, Taylor S, McKay D.

It is illegal to post this copyrighted PDF on any website.

Obsessive-compulsive disorder. *Lancet*. 2009;374(9688):491–499.

10. Purdon C, Clark DA. Obsessive intrusive thoughts in nonclinical subjects, part 1: content and relation with depressive, anxious and obsessional symptoms. *Behav Res Ther*. 1993;31(8):713–720.
11. Rachman S. A cognitive theory of obsessions. *Behav Res Ther*. 1997;35(9):793–802.
12. Murphy DL, Moya PR, Fox MA, et al. Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive-compulsive disorder as an example of overlapping clinical and genetic heterogeneity. *Philos Trans R Soc Lond B Biol Sci*. 2013;368(1615):20120435.
13. Thaipisuttikul P, Ittasakul P, Waleeprakhon P, et al. Psychiatric comorbidities in patients with major depressive disorder. *Neuropsychiatr Dis Treat*. 2014;10:2097–2103.
14. Fullana MA, Mataix-Cols D, Caspi A, et al. Obsessions and compulsions in the community: prevalence, interference, help-seeking, developmental stability, and co-occurring psychiatric conditions. *Am J Psychiatry*. 2009;166(3):329–336.
15. Depression during and after pregnancy, fact sheet 2009. Office on Women’s Health, US Department of Health and Human Services Web site. <https://www.womenshealth.gov/publications/our-publications/fact-sheet/depression-pregnancy.html>. Updated July 16, 2012. Accessed August 24, 2015.
16. Wisner KL, Peindl KS, Gigliotti T, et al. Obsessions and compulsions in women with postpartum depression. *J Clin Psychiatry*. 1999;60(3):176–180.
17. The ICD-10 Classification of Mental and Behavioral Disorders: clinical descriptions and diagnostic guidelines, pp 117. World Health Organization Web site. <http://www.who.int/classifications/icd/en/bluebook.pdf>. Accessed July 23, 2015.
18. Rush AJ, Fava M, Wisniewski SR, et al; STAR*D Investigators Group. Sequenced Treatment Alternatives to Relieve Depression (STAR*D): rationale and design. *Control Clin Trials*. 2004;25(1):119–142.
19. Zimmerman M, Mattia JI. A self-report scale to help make psychiatric diagnoses: the Psychiatric Diagnostic Screening Questionnaire. *Arch Gen Psychiatry*. 2001;58(8):787–794.
20. Zimmerman M. *The Psychiatric Diagnostic Screening Questionnaire*. Los Angeles, CA: Western Psychological Services; 2002.
21. Howland RH, Rush AJ, Wisniewski SR, et al. Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. *Drug Alcohol Depend*. 2009;99(1–3):248–260.
22. Hamilton M. Rating depressive patients. *J Clin Psychiatry*. 1980;41(12 pt 2):21–24.
23. Zimmerman M, Martinez JH, Young D, et al. Severity classification on the Hamilton Depression Rating Scale. *J Affect Disord*. 2013;150(2):384–388.
24. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. *Biol Psychiatry*. 2003;54(5):573–583.
25. Hudon C, Fortin M, Vanasse A. Cumulative Illness Rating Scale was a reliable and valid index in a family practice context. *J Clin Epidemiol*. 2005;58(6):603–608.
26. Brakoulias V, Starcevic V, Berle D, et al. The characteristics of unacceptable/taboo thoughts in obsessive-compulsive disorder. *Compr Psychiatry*. 2013;54(7):750–757.
27. Hofmeijer-Sevink MK, van Oppen P, van Megen HJ, et al. Clinical relevance of comorbidity in obsessive compulsive disorder: the Netherlands OCD Association study. *J Affect Disord*. 2013;150(3):847–854.
28. Kendler KS, Campbell J. Expanding the domain of the understandable in psychiatric illness: an updating of the Jaspersian framework of explanation and understanding. *Psychol Med*. 2014;44(1):1–11.
29. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, 1: development, use, and reliability. *Arch Gen Psychiatry*. 1989;46(11):1006–1011.
30. Shim G, Park HY, Jang JH, et al. What is the optimal dose of escitalopram for the treatment of obsessive-compulsive disorder? a naturalistic open-label study. *Int Clin Psychopharmacol*. 2011;26(5):284–290.

It is illegal to post this copyrighted PDF on any website.



POSTTEST

To obtain credit, go to PSYCHIATRIST.COM (Keyword: December) to take this Posttest and complete the Evaluation. A nominal processing fee is required.

1. Which statement is most accurate?
 - a. Loss and failure are more common themes of obsessions in people with obsessive-compulsive disorder than contamination, symmetry, and harm
 - b. Depressed patients tend to reveal embarrassing and stigmatized obsessions
 - c. The presence of obsessive-compulsive symptoms may interfere with remission of depression
 - d. Intrusive sexual or violent thoughts are uncommon in the general population
2. Mrs B, a 45-year-old woman with nonpsychotic unipolar depression, reluctantly admits that she fears she may be evil because she has longstanding worries that she may unknowingly molest her elderly mother or run over a pedestrian while driving. The most likely comorbid diagnosis is _____.
 - a. Posttraumatic stress disorder
 - b. Obsessive-compulsive disorder
 - c. Cluster A personality disorder
 - d. Traumatic brain injury